- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00947466
A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth Pain (BUP1501)
October 22, 2018 updated by: Mundipharma Research Limited
A Multi Centre Open Label Single Therapy Dose Ranging Study to Characterise the Pharmacokinetics & Tolerability of BTDS 5-20 ug/h in Children Who Require Opioid Analgesia for Moderate to Severe Mouth Pain Secondary to Chemotherapy Induced Mucositis.
The purpose of this study is to characterize the pharmacokinetics and tolerability of buprenorphine patches in children who require opioid pain relief for moderate to severe mouth pain.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Subjects will be screened for eligibility and if eligible will apply a buprenorphine patch (Day 1).
The patch will be worn for 7 days during which time, safety assessments, pain scores, mucositis scores, PK sampling & vital signs will be assessed on each day.
After patch removal subjects will continue with these assessments on a daily basis until Day 12.
The subject will then be followed up for 10 days (to Day 22) to collect information on ongoing/new SAEs/AEs.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Skejby, Denmark
-
-
-
-
-
Liverpool, United Kingdom
- Dr Howell
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 16 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Male or female children experiencing severe mouth pain secondary to chemotherapy induced mucositis requiring opioid analgesic therapy and who will be an inpatient, as a minimum up to Day 8 (patch removal).
- Subjects experiencing 'severe' pain in the Investigators clinical judgment.
- Body weight ≥ 15 kg. Subjects weighing ≥ 25 kg will be recruited in the first phase of the study with those weighing < 25 kg also being included in the second phase, (after a successful review by an IDSMC). Upper age range to be 16 years.
- In dwelling IV cannula or central line from which blood can be obtained.
- Written informed consent obtained from parent(s)/legal representative, and where possible assent obtained from the subject if appropriate, in line with local regulations.
- Females of child bearing potential must have a negative urine pregnancy test if the Principal Investigator considers there to be a reasonable possibility of pregnancy.
Exclusion criteria:
- Subjects with known hypersensitivity to buprenorphine or any of its excipients in the transdermal system, as outlined in the Summary of Product Characteristics for BuTrans.
- Known hypersensitivity to other opioids.
- Skin disease affecting application or local tolerance of BTDS.
- Clinically significant history of allergic reaction to wound dressings or adhesives.
- Severe respiratory impairment.
- Clinically significant hepatic dysfunction.
- Severe renal impairment.
- Subjects who are receiving MAO inhibitors or have taken them within the previous 2 weeks.
- Subjects receiving hypnotics or other central nervous system (CNS) depressants that, in the investigator's opinion, may pose a risk of additional CNS depression with study medication.
- Subjects who have taken any buprenorphine preparations in the last 14 days.
- Subjects with myasthenia gravis.
- Subjects with convulsive disorders, head injury, shock, or reduced level of consciousness of uncertain origin.
- Subjects who are currently participating in another clinical research study involving a new chemical entity (NCE) unless the sole purpose of the other trial at the time of BUP1501 screening is for long term follow-up/survival data or subjects who have participated in a clinical study within the previous 30 days. Participation in a chemotherapy clinical trial that is not evaluating a NCE will be accepted for inclusion.
- Subjects who are pregnant, lactating or in the Investigators opinion are at risk of conceiving.
- Previous enrollment in this clinical study.
- Subjects who the Investigator believes are unsuitable for the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patch
|
Transdermal patch
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To characterise the pharmacokinetics of BTDS 5-20 ug/h in children weighing >15kg
Time Frame: PK's taken daily for 12 days
|
PK's taken daily for 12 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
safety & tolerability of BTDS 5-20ug/h in children
Time Frame: every 4 hours to day 5, day 12 and day 21
|
every 4 hours to day 5, day 12 and day 21
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (Actual)
November 1, 2012
Study Completion (Actual)
November 1, 2012
Study Registration Dates
First Submitted
July 8, 2009
First Submitted That Met QC Criteria
July 27, 2009
First Posted (Estimate)
July 28, 2009
Study Record Updates
Last Update Posted (Actual)
October 24, 2018
Last Update Submitted That Met QC Criteria
October 22, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Stomatognathic Diseases
- Mouth Diseases
- Mucositis
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Narcotic Antagonists
- Buprenorphine
Other Study ID Numbers
- BUP1501
- 2008-002428-27
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy Induced Mucositis
-
Cairo UniversityNot yet recruitingChemotherapy Induced Oral Mucositis
-
University of Science and Technology, YemenCompletedChemotherapy-induced Oral Mucositis
-
Hadassah Medical OrganizationCompletedChemotherapy Induced MucositisIsrael
-
Solasia Pharma K.K.Solasia Medical Information Consulting (Shanghai) Co. Ltd.CompletedChemotherapy- and/or Radiation-induced Oral MucositisChina
-
Mashhad University of Medical SciencesCompletedChemotherapy Induced Oral MucositisIran, Islamic Republic of
-
Hams Hamed AbdelrahmanUnknownOral Mucositis Due to ChemotherapyEgypt
-
Bursa Uludag UniversitesiEnrolling by invitationColon Cancer | Chemotherapy Effect | Oral Mucositis | Nurse's RoleTurkey
-
Cairo UniversityNot yet recruitingChemotherapy Effect | Mucositis Oral
-
Taipei City HospitalCompletedChemotherapy-Induced ChangeTaiwan
-
Careseng Biotech Co., Ltd.UnknownChemotherapy-induced Myelosuppression
Clinical Trials on Buprenorphine
-
Montefiore Medical CenterRecruiting
-
Steve N. Caritis, MDEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingPregnancy | Opiate AddictionUnited States
-
Indivior Inc.CompletedOpioid Use Disorder | Opioid-related DisordersUnited States
-
Indivior Inc.Completed
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)SuspendedExtended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use DisorderOpioid-use DisorderUnited States
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA)Completed
-
Duke UniversityNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCCompletedOpioid Use DisorderUnited States
-
Orexo ABWorldwide Clinical TrialsCompletedOpioid-Related Disorders | Opiate DependenceUnited States